Merrill maintains Amylin at neutral

Amylin Pharmaceuticals was maintained by Merrill Lynch analyst Tom McGahren at neutral after the company preannounced first-quarter 2006 Byetta sales of $68 million. Demand for Byetta is outstripping the pen injector supplier's production schedule, forcing Amylin to reduce efforts to lure new patients, cutting out free samples and coupons. Amylin is working to increase capacity at its pen supplier and bring a second supplier onboard. Shares of the San Diego, Calif., biopharmaceutical company were down $0.78, or 1.72%, at $44.51 on volume of 8,416,813 shares versus the three-month running average of 2,256,420 shares. (Nasdaq: AMLN)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.